{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:37:53Z","timestamp":1762144673301},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,9,2]],"date-time":"2009-09-02T00:00:00Z","timestamp":1251849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:p> <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003The antiobesity drugs sibutramine and orlistat are not licensed for use in children and adolescents in the UK or USA.<\/jats:p><jats:p>\u2022\u2003Clinical trials suggest antiobesity drugs are effective and well\u2010tolerated in obese adolescents.<\/jats:p><jats:p> <jats:bold>WHAT THIS STUDY ADDS<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Prescribing of unlicensed antiobesity drugs in children and adolescents has increased significantly in the past 8 years.<\/jats:p><jats:p>\u2022\u2003Most prescribed antiobesity drugs in children and adolescents are rapidly discontinued before patients can see clinical benefit, suggesting they are poorly tolerated or poorly efficacious.<\/jats:p><jats:p><jats:bold>AIMS<\/jats:bold> The international childhood obesity epidemic has driven increased use of unlicensed antiobesity drugs, whose efficacy and safety are poorly studied in children and adolescents. We investigated the use of unlicensed antiobesity drugs (orlistat, sibutramine and rimonabant) in children and adolescents (0\u201318 years) in the UK.<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold> Population\u2010based prescribing data from the UK General Practice Research Database between 1 January 1999 and 31 December 2006.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold> A total of 452 subjects received 1334 prescriptions during the study period. The annual prevalence of antiobesity drug prescriptions rose significantly from 0.006 per 1000 [95% confidence interval (CI) 0.0007, 0.0113] in 1999 to 0.091 per 1000 (95% CI 0.07, 0.11) in 2006, a 15\u2010fold increase, with similar increases seen in both genders. The majority of prescriptions were made to those \u226514 years old, although 25 prescriptions were made for children &lt;12 years old. Orlistat accounted for 78.4% of all prescriptions; only one patient was prescribed rimonabant. However, approximately 45% of the patients ceased orlistat and 25% ceased sibutramine after only 1 month. The estimated mean treatment durations for orlistat and sibutramine were 3 and 4 months, respectively.<\/jats:p><jats:p><jats:bold>CONCLUSIONS<\/jats:bold> Prescribing of unlicensed antiobesity drugs in children and adolescents has dramatically increased in the past 8 years. The majority are rapidly discontinued before patients can see weight benefit, suggesting they are poorly tolerated or poorly efficacious when used in the general population. Further research into the effectiveness and safety of antiobesity drugs in clinical populations of children and adolescents is needed.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2009.03528.x","type":"journal-article","created":{"date-parts":[[2009,9,2]],"date-time":"2009-09-02T23:06:10Z","timestamp":1251932770000},"page":"844-851","source":"Crossref","is-referenced-by-count":36,"title":["Rise in antiobesity drug prescribing for children and adolescents in the UK: a population\u2010based study"],"prefix":"10.1111","volume":"68","author":[{"given":"Russell M.","family":"Viner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingfen","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Neubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian C. K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,11,27]]},"reference":[{"key":"e_1_2_10_2_2","volume-title":"Tackling Obesities: Future Choices\u2014International Comparisons of Obesity Trends, Determinants and Responses\u2014Evidence Review \u20102 Children","author":"Lobstein T","year":"2007"},{"key":"e_1_2_10_3_2","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/archinte.1994.00420160079011","article-title":"Persistence of multiple cardiovascular risk clustering related to syndrome X from childhood to young adulthood. The Bogalusa Heart Study","volume":"154","author":"Bao W","year":"1994","journal-title":"Arch Intern Med"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.3.712"},{"key":"e_1_2_10_5_2","volume-title":"Healthy Weight, Healthy Lives: a Cross\u2010Government Strategy for England","author":"Cross\u2010Government Obesity Unit DoHDoCSaF","year":"2008"},{"key":"e_1_2_10_6_2","volume-title":"Tackling Obesities: Future Choices \u2013 Modelling Future Trends in Obesity & Their Impact on Health","author":"McPherson K","year":"2007"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/13557850500071095"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2003.036467"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.08.042"},{"key":"e_1_2_10_10_2","unstructured":"National Institute for Health and Clinical Excellence.Obesity: guidance on the prevention identification assessment and management of overweight and obesity in adults and children. NICE Clinical Guideline 43; December 2006."},{"key":"e_1_2_10_11_2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/pubmed\/fdm013","article-title":"National trends in the use and costs of anti\u2010obesity medications in England, 1998\u20132005","volume":"29","author":"Shrishanmuganathan J","year":"2007","journal-title":"J Public Health"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-2329C"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-2008"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2004.064956"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)04248-7"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02450.x"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0803084"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2002.87"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.23.2873"},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666120-00012"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-004-1534-6"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.14.1805"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-2-200607180-00005"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0263"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.05.008"},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0803352"},{"key":"e_1_2_10_27_2","first-page":"580","article-title":"Anti\u2010obesity drug use before professional treatment in Taiwan","volume":"16","author":"Liou TH","year":"2007","journal-title":"Asia Pac J Clin Nutr"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2009.03528.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2009.03528.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T01:08:36Z","timestamp":1697418516000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2009.03528.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,27]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1111\/j.1365-2125.2009.03528.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03528.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,27]]}}}